Anteris Technologies Global Corp.

NASDAQ: AVR · Healthcare · Medical - Devices

PublicHQ Toowong, QLDCIK 0002011514Reports USD

#800 of 1,406 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH 16DQ —GM —SS 49

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ disclosure history, listing tenure

Methodology →

Revenue TTM

$1.9M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$94.1M

Employees

174

Market cap

$306.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.9M$1.9M2025

Net income-$94.1M-$94.1M2025

Operating income-$93.9M-$93.9M2025

Total assets$23.0M$23.0M2025

Liabilities$23.3M$23.3M2025

Equity-$93.0k-$93.0k2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Anteris Technologies Global Corp. booked $1.9M in FY2025 revenue, contracting 29% year over year — slower than 76% of Healthcare companies we track, at a -4921.3% net margin.

Peers · Healthcare

Fennec Pharmaceuticals Inc.61C Carlsmed, Inc.43D Neumora Therapeutics, Inc. Common Stock——Organogenesis Holdings Inc.65B

Key facts

CEOWayne Geoffrey Paterson

SectorHealthcare

IndustryMedical - Devices

HeadquartersToowong, QLD

ExchangeNASDAQ: AVR

Employees174

IPO date2024-12-13

Latest filings

No filings loaded.

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.